(Press-News.org) A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the effectiveness of chimeric antigen receptor (CAR) T cell therapy against glioblastoma, one of the most lethal and treatment-resistant brain tumors. The findings, published in Science Translational Medicine, highlight how gene therapy targeting immune stimulating cytokines to the tumor microenvironment (TME) and enabling their private cross-talk with CAR-T cells not only restores CAR-T killer activity but also boost a broader immune response that inhibits tumor growth and extends host survival in a preclinical glioblastoma models.
The study builds on the prior development by the Naldini's laboratory of a gene therapy strategy that exploit genetic engineering of hematopoietic progenitors to generate a progeny of monocyte/macrophages that selectively release their immune stimulating payload upon infiltrating a tumor. This strategy has been taken to its first-in-human clinical testing as stand-alone treatment of glioblastoma by the biotech company Genenta Science, a spin-off from the San Raffaele Institute now listed on the NASDAQ.
“Solid tumors like glioblastoma have been notoriously difficult for CAR-T cells to penetrate and control,” explains Dr. Rossari, first author of the work, “By reprogramming a population of tumor-infiltrating macrophages to deliver cytokines directly into the tumor, we’ve morphed the immunosuppressive TME into one supportive of immune cells, thus allowing CAR T cells to better persist, become activated and attack tumor cells.”
CAR-T cells have shown transformative results in blood cancers but have struggled in solid tumors due to the hostile, immunosuppressive TME. The team’s strategy leads to selective release of two cytokines within the TME: interferon-α (IFN-α), a pleiotropic immune stimulator that counteracts local immune suppressive cues and enforces antigen presentation and immune effectors’ activity, and an engineered mutant of interleukin-2 that can only activate a cognate mutant receptor co-introduced with the CAR into T cells, thus boosting the proliferation specifically of the administered effector engaged in fighting the tumor.
“The private ‘cross-talk’ between genetically engineered macrophages and CAR T cells established in the TME ensures that the immune stimulants act only where needed, sparing the rest of the body from systemic toxicity, and specifically on the relevant target cells involved in the tumor attack, again preventing collateral damage and aberrant effects,” says Dr. Alvisi, co-first author of the study.
In a mouse model of glioblastoma that mimics the pathology and immunological barriers seen in human patients, the targeted cytokines rescued the activity of CAR-T cells that, given alone, were ineffective – as mostly seen in clinical trials. In turn, the rescued CAR T cells now synergized with cytokine delivery, significantly enhancing their effect on delaying tumor growth and extending mouse survival. Strikingly, even tumors with only a fraction of cells expressing the CAR-targeted antigen B7-H3 were effectively controlled, indicating engagement of endogenous T cells on top of the CAR-T to fight the tumor.
“We observed not only reactivation of the CAR-T cells but also the recruitment of the host’s own T cells against a wider range of tumor antigens,” says Dr. Nadia Coltella, senior co-corresponding author. “This phenomenon, known as antigenic spreading, was mostly dependent on IFN-α activity in the TME and is a key feature for creating effective immunity as it may overcome immune evasion by tumors targeted only through a single antigen by the CAR-T cells.”
“This work represents another important step forward in our decade-long commitment to develop a novel gene and cell therapy strategy effective against tumors, as we have been able to do for several genetic diseases along the life of our institute” adds Luigi Naldini, Director of SR-TIGET and Professor at Università Vita-Salute San Raffaele. “The tumor-targeted IFN-α delivery strategy is already being evaluated as stand-alone treatment in a first-in-human phase 1/2a trial on the most aggressive type of glioblastoma (Temferon trial) led by the biotech company Genenta Science. The study has shown feasibility, safety, biological activity in reprogramming the TME and early but promising indication of therapeutic benefit, albeit limited by the small number of treated patients and the design of a phase 1 study. A combination of Temferon with CAR-T cells administration, as prompted by our new study, could in future further enhance the benefit of the treatment and broaden its efficacy to a larger fraction of patients.”
This study was supported also by the Italian Association for Cancer Research (AIRC), the Louis-Jeantet Foundation through the Jeantet-Collen Prize for Translational Medicine to Luigi Naldini, and a research contract from Genenta Sciences.
END
Engineered cell cross-talk unlocks CAR-T potential against glioblastoma
Scientists at San Raffaele-Telethon Institute for Gene Therapy develop a cytokine delivery platform that reprograms the tumor microenvironment and enhances CAR-T cell function in preclinical brain cancer models
2025-07-02
ELSE PRESS RELEASES FROM THIS DATE:
Regional disparities in US media coverage of archaeology research
2025-07-02
What archaeological discoveries are considered newsworthy by U.S. media outlets and audiences? A new analysis of “pop-science” reporting reveals topical and regional disparities, including an apparent underrepresentation of Chinese archaeology and preference for findings relevant to white Christian histories. The skewed coverage raises concerns as archaeology influences notions of identity and cultural achievement, and has been misappropriated by racist, nationalist ideologies.
Mass ...
Coral larvae travelling further makes populations stronger
2025-07-02
Understanding how far Great Barrier Reef corals are from their parents could be key to identifying and protecting at risk populations, University of Queensland research has found.
PhD candidate Zoe Meziere said well-connected coral populations had a better chance of adapting to climate change and other environmental pressures.
“Quantifying genetic connectivity can predict the fate of populations as more isolated reefs with lower levels of genetic variation are likely more vulnerable,” Ms Meziere said.
“Species that don’t disperse or breed as far are more likely to form isolated populations, reducing their capacity to recover from bleaching events ...
First of its kind study for children with arthritis reveals possible new disease targets
2025-07-02
A new groundbreaking study by researchers from University of Birmingham, UCL, Great Ormond Street Hospital and Birmingham Children’s Hospital has revealed important clues into what is driving disease in children with arthritis.
Cutting-edge techniques have allowed scientists for the first time to uncover the unique architecture of cells and signals inside the joint as inflammation takes hold.
The new study published in Science Translational Medicine looks at arthritis in children, caused by the immune system mistakenly attacking joints. Juvenile idiopathic arthritis affects more than 10,000 children in the UK. It causes swelling, ...
Financing innovation: proposal for novel adaptive platform trial fund offers new model for ALS drug development
2025-07-02
A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), Questrom School of Business at Boston University, and QLS Advisors have introduced a new approach to funding clinical trials for amyotrophic lateral sclerosis (ALS) therapies. The study “Financing Drug Development via Adaptive Platform Trials,” published today in PLOS One, outlines a financing model that merges the efficiencies of adaptive platform trials — lower costs and shorter durations — with an innovative royalty-based investment structure designed to accelerate therapeutic development ...
Disparities in treatment and referral after an opioid overdose among emergency department patients
2025-07-02
About The Study: In this study, Black patients were less likely to receive outpatient referrals for opioid use disorder. These findings underscore the need for targeted interventions to address racial disparities in emergency department care for opioid use disorder, particularly in enhancing referral processes.
Corresponding Author: To contact the corresponding author, Siri Shastry, MD, MS, email Siri.Shastry@mountsinai.org.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.18569)
Editor’s Note: Please ...
Was Mars doomed to be a desert? Study proposes new explanation
2025-07-02
One of the great unsolved problems in modern planetary science is written on the surface of Mars.
Mars has canyons that were carved by rivers, so it was once warm enough for liquid water. How—and why—did it become it a barren desert today?
A study led by University of Chicago planetary scientist Edwin Kite puts forth a new explanation for why Mars never seems to stay balmy for long. Published July 2 in Nature, their model suggests that the periods of liquid water we see in the past were initiated by the sun brightening, and that conditions on Mars mean it ...
Study highlights major hurdles for multinational clinical trials in Europe
2025-07-02
Study Highlights Major Hurdles for Multinational Clinical Trials in Europe
A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on significant ethical, administrative, regulatory, and logistical (EARL) hurdles in delivering multinational randomized clinical trials. The research was the first to comprehensively quantify these barriers for an international platform trial and emphasizes the need for urgent improvements, particularly in preparing for future public health crises.
Randomized controlled trials provide the highest level of evidence to inform medical practice. Yet, delivering such trials ...
Chemistry breakthrough has potential to make more effective cancer drugs with less harmful side effects
2025-07-02
Chemists have discovered for the first time a unique way to control and modify a type of compound widely used in medicines, including a drug used to treat breast cancer.
The research, led by the University of Bristol and published today in the journal Nature, also found a new mechanism associated with the chemical reaction which enables the shape of the compound to be flipped from being right-handed to left-handed by simply adding a common agent in the chemical reaction.
Study lead author Varinder Aggarwal, Professor of Synthetic Chemistry at the University of Bristol, said: “The findings change our understanding of the fundamental chemistry of this group of organic ...
Researchers identify new protein target to control chronic inflammation
2025-07-02
Chronic inflammation occurs when the immune system is stuck in attack-mode, sending cell after cell to defend and repair the body for months or even years. Diseases associated with chronic inflammation, like arthritis or cancer or autoimmune disorders, weigh heavily on human health—and experts anticipate their incidence is on the rise. A new study by investigators from Mass General Brigham identified a protein called WSTF that could be targeted to block chronic inflammation. Crucially, this strategy would not ...
Increasing contingency management incentives will help more patients recover from addiction
2025-07-02
Early recovery from drug addiction to opioids and stimulants is physically and mentally demanding, and a long road to recovery.
“During the early stages of addiction recovery there is typically not much that is positive for patients,” shares behavioral health counselor Carla J. Rash, Ph.D. of UConn School of Medicine. “But Contingency Management is an effective, behavioral tool bringing some early-on positivity to a patient’s addiction recovery treatment plan until the positive benefits of their medication and body’s natural recovery kicks-in.”
Rash adds, “Essentially, ...
LAST 30 PRESS RELEASES:
Enhancing the “feel-good” factor of urban vegetation using AI and street view images
A single genetic mutation may have made humans more vulnerable to cancer than chimpanzees
Innovative nanocomposite hydrogel shows promise for cartilage regeneration in osteoarthritis treatment
2025 Guangci Laboratory Medicine Innovation and Development Conference
LabMed Discovery is included in the ICI World Journals database
LabMed Discovery is included in the China Open Access Journal (COAJ) database
Vaccination support program reduces pneumonia-related mortality by 25 percent among the elderly
Over decades, a healthy lifestyle outperforms metformin in preventing onset of Type 2 diabetes
Mental health disorders, malaria, and heart disease most affected by covid pandemic
Green transition will boost UK productivity
Billions voted in 2024, but major new report exposes cracks in global democracy
Researchers find “forever chemicals” impact the developing male brain
Quantum leap in precision sensing across technologies
Upgrading biocrude oil into sustainable aviation fuel using zeolite-supported iron-molybdenum carbide nanocatalysts
For effective science communication, ‘just the facts’ isn’t good enough
RT-EZ: A golden gate assembly toolkit for streamlined genetic engineering of rhodotorula toruloides
Stem Cell Reports announces five new early career editors
Support networks may be the missing link for college students who seek help for excessive drinking
The New England Journal of Medicine shines spotlight on forensic pathology
Scientists discover protein that helps lung cancer spread to the brain
Perceived social status tied to cardiovascular risks in women but not in men
Brain tumor growth patterns may help inform patient care management
This might be America's first campus tree inventory
Emoji use may impact relationship outcomes
Individual merit, not solidarity, prioritized by early childhood education policies
Preclinical study unlocks a mystery of rapid mouth healing
Extraterrestrial habitats: bioplastics for life beyond earth
U.S. military spending reductions could substantially lower energy consumption
Air pollution is linked to adverse birth outcomes in India
Using viral load tests to help predict mpox severity when skin lesions first appear
[Press-News.org] Engineered cell cross-talk unlocks CAR-T potential against glioblastomaScientists at San Raffaele-Telethon Institute for Gene Therapy develop a cytokine delivery platform that reprograms the tumor microenvironment and enhances CAR-T cell function in preclinical brain cancer models